10-Q: Zura Bio Advances Phase 2 Trials Amidst Increased R&D Spend

Zura Bio Limited reported increased R&D expenses for its lead product candidates and a higher net loss for the nine months ended September 30, 2025, while maintaining liquidity through 2027.

Summary

• Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.
• The company's lead product candidate, tibulizumab (ZB-106), is in two ongoing Phase 2 clinical studies: TibuSHIELD for hidradenitis suppurativa (HS) and TibuSURE for early diffuse cutaneous systemic sclerosis (dcSSc).
• TibuSHIELD, initiated in May 2025, is evaluating tibulizumab in approximately 180 adults with moderate to severe HS, with topline results expected in Q3 2026.
• TibuSURE, initiated in December 2024, is evaluating tibulizumab in approximately 80 adults with early dcSSc, with topline results expected in Q4 2026.
• Research and development expenses significantly increased by $5.9 million (98%) for the three months ended September 30, 2025, and by $16.0 million (105%) for the nine months ended September 30, 2025, compared to the same periods in 2024, primarily due to advancing Phase 2 clinical trials.
• Net loss for the three months ended September 30, 2025, was $(18.0) million, an improvement from $(20.7) million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $(51.5) million, a worsening from $(38.8) million in the prior year period.
• The accumulated deficit reached $(207.4) million as of September 30, 2025, up from $(155.9) million at December 31, 2024.
• Cash and cash equivalents stood at $139.0 million as of September 30, 2025, down from $176.5 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, increased to $(42.5) million from $(17.3) million in the prior year period.
• The company expects its existing cash, cash equivalents, and investments to be sufficient to fund operations through 2027.
• An internal review by the audit committee is ongoing regarding agreements and relationships with BAFFX17 and Stone Peach, leading to deferred payments of a $5.0 million milestone and the settlement of a Put Option and Put Right.

Sentiment

Score: 4

Explanation: While clinical trials are progressing and liquidity is projected for two years, the significant increase in cash burn, substantial year-over-year net loss increase, reduced financing activity, ongoing internal review, and management changes introduce considerable uncertainty and risk, outweighing the positive clinical advancements.

Positives

• Advancement of lead product candidate, tibulizumab (ZB-106), into two global Phase 2 clinical studies (TibuSHIELD for HS and TibuSURE for dcSSc).
• Projected liquidity to fund operating expenses and capital requirements through 2027, providing a runway for ongoing development.
• Net loss for the three months ended September 30, 2025, improved to $(18.0) million from $(20.7) million in the same period last year.
• Successful exercise of Pre-Funded Warrants, resulting in the issuance of 2,888,952 Class A Ordinary Shares during the nine months ended September 30, 2025.

Negatives

• Significant increase in net loss for the nine months ended September 30, 2025, to $(51.5) million from $(38.8) million in the prior year period.
• Accumulated deficit increased to $(207.4) million as of September 30, 2025, indicating continued operating losses.
• Cash and cash equivalents decreased to $139.0 million as of September 30, 2025, from $176.5 million at December 31, 2024.
• Net cash used in operating activities more than doubled to $(42.5) million for the nine months ended September 30, 2025, compared to $(17.3) million in the prior year period, indicating a higher cash burn rate.
• Net cash provided by financing activities significantly decreased to $5.2 million for the nine months ended September 30, 2025, from $110.7 million in the prior year period.
• Ongoing internal review by the audit committee regarding agreements with BAFFX17 and Stone Peach, which has led to deferred payments and introduces uncertainty.
• CEO Robert Lisicki commenced a medical leave of absence, leading to the appointment of an interim CEO.

Risks

• Product candidates and their related benefits may not be achieved, and competing products may be more successful.
• Timing of key events, study initiation, and clinical data release may take longer than anticipated or not be achieved.
• Inability to attract and retain key personnel, including managerial, scientific, and medical staff, could adversely affect business strategy.
• Requirement for substantial additional capital to finance operations; inability to raise capital could force delays or elimination of development programs.
• Reliance on third-party contract development manufacturing organizations (CDMOs) and contract research organizations (CROs) for clinical materials and trials.
• Inability to obtain regulatory approval for product candidates, or related restrictions/limitations on approved products.
• Exposure to general economic and geopolitical conditions, including international trade policies, tariffs, and supply chain disruptions.
• Challenges in effectively managing growth as a clinical-stage company.
• Inability to adequately protect intellectual property rights.
• Disruptions at regulatory agencies (FDA, EMA, European Commission) due to funding shortages or government shutdowns could delay approvals.
• Increased research and development expenses and supply chain complexity due to current or future tariffs, especially with non-U.S. suppliers.
• Preclinical and clinical development is lengthy, expensive, and uncertain, with no guarantee that earlier results predict future success.
• High placebo response rates in dermatologic conditions like HS may complicate the interpretation of clinical results.
• Substantial competition from major pharmaceutical and biotechnology companies developing similar mechanisms of action.
• Healthcare legislative and regulatory reforms (e.g., IRA, OBBBA, potential Most-Favored-Nation pricing, march-in rights) could adversely impact profitability and pricing.
• Subject to laws and regulations related to privacy, data protection, and information security (GDPR, UK GDPR, U.S. Department of Justice rule on sensitive personal data), with potential for fines, litigation, and reputational harm from non-compliance or breaches.
• Internal computer systems or those of third parties may fail or suffer security/data privacy breaches, leading to costs, liabilities, and operational disruption.
• The ongoing internal review of certain agreements and other matters (BAFFX17 and Stone Peach) could materially adversely impact business, reputation, financial condition, and results of operations.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future and may never become profitable. Expenses are anticipated to increase significantly due to ongoing preclinical and clinical development, manufacturing scale-up, regulatory compliance, and commercialization efforts. Existing cash, cash equivalents, and investments are projected to fund operations through 2027, but additional financing will be required to achieve business objectives, with no assurance of availability on acceptable terms. Topline results for the TibuSHIELD Phase 2 study are expected in Q3 2026, and for the TibuSURE Phase 2 study in Q4 2026. The company expects to no longer be an emerging growth company effective December 31, 2026.

Management Comments

• We continue to monitor timelines and evaluate strategy in light of the competitive landscape for conducting clinical trials, competition for enrollment of patients, and external events, including those potentially impacting regulatory matters and overall study execution.
• We are actively assessing the competitive landscape and evaluating potential therapeutic indications for crebankitug.
• We continue to monitor publicly available clinical data from other IL-33/ST2-targeted programs to inform future development plans for torudokimab.
• Our estimate as to how long we expect our existing cash and cash equivalents to be able to fund our operating expenses and capital requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.

Industry Context

Zura Bio operates in the highly competitive biotechnology and pharmaceutical industries, specifically focusing on immunology for autoimmune and inflammatory diseases. The company faces competition from major pharmaceutical and biotechnology companies worldwide, including those developing IL-7R, TSLPR, IL-33, ST2, IL-17A, and BAFF inhibitors. The industry is also subject to significant regulatory scrutiny and evolving healthcare legislative reforms, such as the Inflation Reduction Act and the One Big Beautiful Bill Act, which aim to control drug pricing and may impact profitability. Geopolitical conditions, including international trade policies and tariffs, also pose risks to global supply chains and R&D costs for companies relying on international manufacturing and raw material sourcing.

Comparison to Industry Standards

• The company's lead product candidate, tibulizumab, targets IL-17A and BAFF, which are pathways also targeted by competitors like MoonLake Immunotherapeutics, UCB SA, Novartis AG (IL-17A inhibitors), and GSK plc, Novartis AG (BAFF inhibitors).
• Crebankitug targets IL-7R, a pathway also pursued by Q32 Bio Inc. and OSE Immunotherapeutics SA.
• Torudokimab targets IL-33, with competitors like Regeneron Pharmaceuticals, Inc. / Sanofi and AstraZeneca plc also having programs in this area. Some IL-33/ST2 programs have reported mixed Phase 2b and Phase 3 trial results, indicating the challenging nature of this target.
• The company's significant R&D spend increase (98% for Q3, 105% for YTD) is typical for a clinical-stage biotech advancing multiple Phase 2 trials, aligning with industry trends of high investment in late-stage development.
• The accumulated deficit and ongoing operating losses are standard for early-stage biopharmaceutical companies prior to product commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings and is not aware of any material pending or threatened claims.
• The audit committee of the board of directors formed an audit subcommittee to review agreements and relationships with BAFFX17 and Stone Peach, among other matters. This review is ongoing, and the company has not made requested payments related to a $5.0 million milestone to BAFFX17 or the settlement of Stone Peach's Put Option and Put Right.

Related Party Transactions

• Stone Peach Properties, LLC: Receives an annual payment of $0.7 million (increasing 10% annually) for the tibulizumab license. Received a one-time payment of $4.5 million in June 2025 for IND acceptance/clinical trial commencement. Has contingent payment obligations including a $25 million milestone and a 2% royalty on net sales. Exercised a Put Option to sell 50% of Z33 Series Seed Preferred Shares for $5.0 million (payment pending internal review). Exercised a Put Right to sell 50% of Z33 Series Seed Preferred Shares in exchange for 2,000,000 Class A Ordinary Shares (settlement pending internal review).
• BAFFX17 Ltd: Received an invoice on June 30, 2025, for a $5.0 million milestone payment as a finders fee for the 2023 Lilly License (payment pending internal review). Is entitled to a fee equal to 3% of any milestone or royalty payments due to Lilly.

Stakeholder Impact

• Shareholders: Face increased dilution risk from potential future capital raises (ATM program) and the exercise of warrants. The ongoing internal review and management changes introduce uncertainty. Increased R&D spend could lead to future value if product candidates succeed, but current losses and cash burn are negative.
• Employees: Changes in management (new CFO, interim CEO) and the ongoing internal review could impact morale and stability. Share-based compensation remains a significant component of overall compensation.
• Customers (future): Potential for new therapies for autoimmune and inflammatory diseases if product candidates achieve regulatory approval.
• Creditors/Suppliers: The company's liquidity position through 2027 provides some assurance, but increased cash burn and deferred payments to related parties (BAFFX17, Stone Peach) due to internal review could raise concerns.
• Regulatory Authorities: Subject to scrutiny regarding clinical trial conduct and compliance with evolving data privacy regulations.

Next Steps

• Continue to advance the preclinical and clinical development of product candidates.
• Initiate and complete additional trials of future potential product candidates.
• Scale up clinical and regulatory capabilities.
• Manufacture current good manufacturing practices (cGMP) material for clinical trials or potential commercial sales.
• Hire additional clinical, quality, regulatory, manufacturing, scientific, and administrative personnel.
• Establish a commercialization infrastructure and scale up manufacturing and distribution capabilities for approved products.
• Adapt regulatory compliance efforts for marketed products.
• Seek regulatory approval for product candidates that successfully complete clinical trials.
• Maintain, expand, and protect intellectual property portfolio.
• Add operational, financial, and management information systems and personnel.
• Address the ongoing internal review of agreements with BAFFX17 and Stone Peach, including requested payments.
• Monitor timelines and evaluate strategy for clinical trials in light of competitive landscape and external events.
• Monitor publicly available clinical data from other IL-33/ST2-targeted programs to inform future development plans for torudokimab.
• Topline results for TibuSHIELD Phase 2 study expected in Q3 2026.
• Topline results for TibuSURE Phase 2 study expected in Q4 2026.
• Decision or payment regarding Z33 financing and 2022 Lilly License by December 7, 2025.

Key Dates

Recommendation

Zura Bio is a clinical-stage company with significant R&D investments in promising dual-pathway antibodies for autoimmune diseases. The projected liquidity through 2027 provides a reasonable runway for ongoing Phase 2 trials. However, the substantial increase in cash burn, the year-over-year increase in net loss, and the significant reduction in financing activities compared to the prior year raise concerns about long-term capital needs. The ongoing internal review of key agreements and recent management changes (CEO medical leave, interim CEO) introduce additional layers of uncertainty and potential operational disruption. While the clinical progress is positive, these financial and governance-related risks warrant a cautious 'hold' stance. Investors should monitor the outcome of the internal review, future financing activities, and clinical trial results closely before making further investment decisions.

Keywords

Zura Bio Limited, tibulizumab, ZB-106, hidradenitis suppurativa, HS, systemic sclerosis, dcSSc, IL-17A, BAFF, immunology, autoimmune diseases, inflammatory diseases, clinical trials, Phase 2, biotechnology, drug development, SEC filing, 10-Q, crebankitug, ZB-168, IL-7R, torudokimab, ZB-880, IL-33, liquidity, R&D expenses, net loss